Journal article
HBV mutations in untreated HIV-HBV co-infection using genomic length sequencing
J Audsley, M Littlejohn, L Yuen, J Sasadeusz, A Ayres, C Desmond, T Spelman, G Lau, GV Matthews, A Avihingsanon, E Seaberg, F Philp, M Saulynas, K Ruxrungtham, GJ Dore, SA Locarnini, CL Thio, SR Lewin, PA Revill
Virology | Published : 2010
Abstract
HIV infection has a significant impact on the natural progression of hepatitis B virus (HBV) related liver disease. In HIV-HBV co-infected patients, little is known about mutations in the HBV genome, which can influence severity of liver disease. The aim of this study was to characterize and to determine the frequency of known clinically significant mutations in the HBV genomes from HIV-HBV co-infected patients and from HBV mono-infected patients. To accomplish this, genomic length HBV sequencing was performed in highly-active anti-retroviral therapy (HAART)-naïve HIV-HBV co-infected patients (n=74) and in anti-HBV therapy-naïve HBV mono-infected patients (n=55).The frequency of HBV mutation..
View full abstractGrants
Awarded by National Institutes of Health
Funding Acknowledgements
We thank Professor Kit Fairley, Melbourne Sexual Health Centre, Melbourne Australia; Dr Robert Finlayson, Taylor Square Private Clinic, Darlinghurst Australia; Professor David Cooper, St Vincent's Hospital, Sydney Australia and Ms Pip Marks, NCHECR, Sydney Australia for their assistance in participant recruitment. We thank Dr. Stephane Hue for helpful advice with the phylogenetic analysis. We acknowledge funding from the National Institute of Health RO1 A1060449. Some of the data in this manuscript were collected by the Multicenter AIDS Cohort Study (MACS) with centers (Principal Investigators) at The Johns Hopkins Bloomberg School of Public Health (Joseph B. Margolick, Lisa P. Jacobson), Howard Brown Health Center, Feinberg School of Medicine, Northwestern University, and Cook County Bureau of Health Services (John P. Phair, Steven M. Wolinsky), University of California, Los Angeles (Roger Detels), and University of Pittsburgh (Charles R. Rinaldo). The MACS is funded by the National Institute of Allergy and Infectious Diseases, with additional supplemental funding from the National Cancer Institute, UO1-AI-35042, UL1-RR025005 (GCRC), UO1-AI-35043, UO1-AI-35039, UO1-AI-35040, UO1-AI-35041. Website located at http://www.statepi.jhsph.edu/macs/macs.html.